Beam Therapeutics Inc. (BEAM) Financial Statements (2026 and earlier)

Company Profile

Business Address	26 LANDSDOWNE STREET CAMBRIDGE, MA 02139
State of Incorp.	DE
Fiscal Year End	December 31
Industry (SIC)	2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info	Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

	12/31/2025 Q4	9/30/2025 Q3	6/30/2025 Q2	3/31/2025 Q1	12/31/2024 Q4	9/30/2024 Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:	1,200,000	1,100,000	1,200,000	1,200,000	850,700	925,800
Cash and cash equivalent	294,944	267,960	282,132	527,907	281,967	230,203
Short-term investments	950,266	807,010	868,205	692,045		695,554
Other undisclosed cash, cash equivalents, and short-term investments	(45,210)	25,030	49,663	(19,952)	568,733	43
Other undisclosed current assets	68,688	(1,453)	(24,536)	47,614	27,449	19,734
Total current assets:	1,268,688	1,098,547	1,175,464	1,247,614	878,149	945,534
Noncurrent Assets
Operating lease, right-of-use asset	100,679	96,995	99,568	102,216	104,865	104,704
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization	104,500	108,290	108,824	109,569	111,412	113,502
Restricted cash and investments	6,676	6,656	6,633	6,610	8,144	6,549
Other noncurrent assets	634	593	668	911	1,254	1,078
Total noncurrent assets:	212,489	212,534	215,693	219,306	225,675	225,833
TOTAL ASSETS:	1,481,177	1,311,081	1,391,157	1,466,920	1,103,824	1,171,367
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities	46,016	32,437	27,882	21,075	36,635	23,650
Accounts payable	10,231	9,545	10,556	7,699	3,871	3,812
Accrued liabilities	35,785	22,892	17,326	13,376	32,764	19,838
Deferred revenue	6,659	110,320	105,822	85,204	108,858	89,327
Derivative instruments and hedges, liabilities	7,700	6,500	3,900	5,200	8,400	8,400
Business combination, contingent consideration, liability	2,714	1,192
Other undisclosed current liabilities	33,846	32,110	36,527	30,067	28,173	44,867
Total current liabilities:	96,935	182,559	174,131	141,546	182,066	166,244
Noncurrent Liabilities
Long-term debt and lease obligation
Long-term debt, excluding current maturities
Liabilities, other than long-term debt	145,884	162,520	170,213	202,238	188,213	213,806
Deferred revenue		10,160	20,319	49,403	33,218	57,816
Other liabilities	173	266	357	414	504	481
Operating lease, liability	139,759	138,732	141,854	144,919	147,956	149,129
Business combination, contingent consideration, liability	5,952	6,708	1,186	1,158	1,131	1,104
Derivative instruments and hedges, liabilities		6,654	6,497	6,344	5,404	5,276
Total noncurrent liabilities:	145,884	162,520	170,213	202,238	188,213	213,806
Total liabilities:	242,819	345,079	344,344	343,784	370,279	380,050
Equity
Equity, attributable to parent	1,238,358	966,002	1,046,813	1,123,136	733,545	791,317
Common stock	1,017	1,014	1,008	1,006	836	826
Additional paid in capital	2,877,449	2,855,118	2,823,987	2,797,871	2,298,661	2,265,009
Accumulated other comprehensive income (loss)	1,111	790	10	160	679	1,759
Accumulated deficit	(1,641,219)	(1,890,920)	(1,778,192)	(1,675,901)	(1,566,631)	(1,476,277)
Total equity:	1,238,358	966,002	1,046,813	1,123,136	733,545	791,317
TOTAL LIABILITIES AND EQUITY:	1,481,177	1,311,081	1,391,157	1,466,920	1,103,824	1,171,367

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

	12/31/2025 Q4	9/30/2025 Q3	6/30/2025 Q2	3/31/2025 Q1	12/31/2024 Q4	9/30/2024 Q3
Revenues	114,109	9,698	8,466	7,470	30,067	14,269
Gross profit:	114,109	9,698	8,466	7,470	30,067	14,269
Operating expenses	(131,554)	(136,509)	(128,617)	(126,756)	(130,104)	(120,773)
Operating loss:	(17,445)	(126,811)	(120,151)	(119,286)	(100,037)	(106,504)
Nonoperating income	261,742	14,083	17,860	10,016	9,683	9,836
Investment income, nonoperating	258,404			3,849	4,640
Net income (loss) available to common stockholders, diluted:	244,297	(112,728)	(102,291)	(109,270)	(90,354)	(96,668)

Comprehensive Income ($ in thousands)
Annual | Quarterly

	12/31/2025 Q4	9/30/2025 Q3	6/30/2025 Q2	3/31/2025 Q1	12/31/2024 Q4	9/30/2024 Q3
Net income (loss):	244,297	(112,728)	(102,291)	(109,270)	(90,354)	(96,668)
Comprehensive income (loss):	244,297	(112,728)	(102,291)	(109,270)	(90,354)	(96,668)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent	321	780	(150)	(519)	(1,080)	2,869
Comprehensive income (loss), net of tax, attributable to parent:	244,618	(111,948)	(102,441)	(109,789)	(91,434)	(93,799)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Financial Reporting
and Analysis Software

Beam Therapeutics Inc. (BEAM) Financial Statements (2026 and earlier)

Company Profile

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

Comprehensive Income ($ in thousands)
Annual | Quarterly

Statements Sources

Login to ReadyRatios

Financial Reportingand Analysis Software

Beam Therapeutics Inc. (BEAM) Financial Statements (2026 and earlier)

Company Profile

Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly

Income Statement (P&L) ($ in thousands)Annual | Quarterly

Comprehensive Income ($ in thousands)Annual | Quarterly

Statements Sources

Login to ReadyRatios

Financial Reporting
and Analysis Software

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

Comprehensive Income ($ in thousands)
Annual | Quarterly